Comparison

Eloralintide vs. Lixisenatide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Lixisenatide

Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Eloralintide	Lixisenatide
Germany	Unapproved	Prescription
JP	—	Prescription
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Eloralintide and Lixisenatide?: Eloralintide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Lixisenatide?: The highest available evidence level is "Human RCT" for Eloralintide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Lixisenatide in Germany and the United States?: Germany: Eloralintide — Unapproved, Lixisenatide — Prescription. United States: Eloralintide — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Lixisenatide

Germany

Unapproved

Prescription

—

Prescription

United States

Unapproved

Frequently asked questions

What is the difference between Eloralintide and Lixisenatide?

Eloralintide is classified as "Metabolic", while Lixisenatide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Lixisenatide?

The highest available evidence level is "Human RCT" for Eloralintide and "Human RCT" for Lixisenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Lixisenatide in Germany and the United States?

Germany: Eloralintide — Unapproved, Lixisenatide — Prescription. United States: Eloralintide — Unapproved, Lixisenatide — Unapproved. These are factual summaries with source and review date on the individual pages.